CN103254126A - Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds - Google Patents

Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds Download PDF

Info

Publication number
CN103254126A
CN103254126A CN2013101761325A CN201310176132A CN103254126A CN 103254126 A CN103254126 A CN 103254126A CN 2013101761325 A CN2013101761325 A CN 2013101761325A CN 201310176132 A CN201310176132 A CN 201310176132A CN 103254126 A CN103254126 A CN 103254126A
Authority
CN
China
Prior art keywords
deuterium
compound
phenyl
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013101761325A
Other languages
Chinese (zh)
Inventor
吴国璋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zelgen Biopharmaceutical Co Ltd
Original Assignee
Suzhou Zelgen Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zelgen Biopharmaceutical Co Ltd filed Critical Suzhou Zelgen Biopharmaceutical Co Ltd
Priority to CN2013101761325A priority Critical patent/CN103254126A/en
Publication of CN103254126A publication Critical patent/CN103254126A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Pyridine Compounds (AREA)

Abstract

The invention relates to deuterated omega-diphenyl carbamide as well as a derivative and a pharmaceutically acceptable salt thereof. The invention further relates to a pharmaceutical composition including a pharmaceutically acceptable carrier, deuterated omega-diphenyl carbamide and the derivative and pharmaceutical and the pharmaceutically acceptable salt. The deuterated omega-diphenyl carbamide disclosed by the invention can be used for treating and preventing cancers and associated diseases.

Description

ω-diphenyl urea and the derivative in deuterium generation and the pharmaceutical composition that comprises this compound
The application is to be September 19, application number in 2008 the dividing an application for the application for a patent for invention of " ω-diphenyl urea and the derivative in deuterium generation and the pharmaceutical composition that comprises this compound " that be 201110302329.X, denomination of invention the applying date.
Application number be the application of 201110302329.X be that September 19, application number in 2008 are 200810200106.0 the applying date, denomination of invention divides an application for the application for a patent for invention of " ω-diphenyl urea and the derivative in deuterium generation and the pharmaceutical composition that comprises this compound ".
Technical field
The present invention relates to ω-diphenyl urea and the derivative in deuterium generation and the pharmaceutical composition that contains this compound.
Background technology
Known ω-diphenyl urea derivatives is the compound of c-RAF kinase activity.The diphenyl urea that one class ω-carboxyl aryl replaces is for example disclosed in WO2000/042012, and the purposes in treatment cancer and relative disease.
ω-diphenyl urea compound such as Xarelto (Sorafenib) are found to be the kinase whose inhibitor of c-RAF at first, discover constantly that afterwards it can also suppress activity (the Curr Pharm Des2002 of the Tyrosylprotein kinase of vascular endothelial growth factor-2 (VEGFR-2), vascular endothelial growth factor-3 (VEGFR-3) and platelet derived growth factor-β (PDGFR-β); 8:2255 – 2257), so it is referred to as many kinase inhibitor, has dual antitumor action.
Xarelto (Sorafenib), trade(brand)name Nexavar, be a kind of novel oral many kinase inhibitor by the common development of Beyer Co., Ltd and ONXY company, since it at one at the excellent performance in the III phase clinical study of kidney in late period, fast ratified to be used for the treatment of late period renal cell carcinoma by FDA in December, 2005, and go on the market in China in November, 2006.
Yet this area still needs to develop has the compound that suppresses active or better pharmacodynamics performance to the raf kinases.
Summary of the invention
Purpose of the present invention just provides novel compound with raf kinase inhibiting activity and better pharmacodynamics performance of a class and uses thereof.
In a first aspect of the present invention, provide ω-diphenyl urea compound or its crystal formation, pharmacy acceptable salt, hydrate or the solvate in the deuterium generation shown in a kind of formula (I):
Figure BDA00003182473800021
In the formula:
R 1Be halogen (as F, Cl, or Br), the C1-C4 alkyl in deuterium one or many deuterium generation or full generation;
R 2Be deuterium generation, one or many deuterium generation or the full deuterium C1-C4 alkyl in generation, the perhaps part or all of C1-C4 alkyl that replaces of halogen;
R 3Be hydrogen, deuterium or halogen (as F, Cl, or Br);
R 4Be hydrogen, deuterium, or halogen (as F, Cl, or Br);
R 5Be hydrogen, deuterium or halogen (as F, Cl, or Br);
R 6It is C1-C4 alkyl hydrogen, deuterium or one or many deuterium generation or full deuterium generation;
R 7It is C1-C4 alkyl hydrogen, deuterium or one or many deuterium generation or full deuterium generation;
Supplementary condition are R 2, R 3, R 4, R 5, R 6Or R 7In at least one be deuterium generation or deuterium.
In another preference, deuterium is greater than natural deuterium isotopic content (0.015%) in the deuterium isotopic content of deuterium the position of substitution at least, preferably greater than 30%, more preferably greater than 50%, more preferably greater than 75%, more preferably greater than 95%, more preferably greater than 99%.
In another preference, formula (I) compound contains 1 D atom at least, more preferably 3 D atoms, more preferably 5 D atoms.
In another preference, R 6Or R 7Be independently selected from respectively: the ethyl in the methyl in deuterium generation or deuterium generation; More preferably, be selected from a deuterium methyl, two deuterium methyl, three deuterium methyl, a deuterium ethyl, two deuterium ethyls, three deuterium ethyls, four deuterium ethyls or five deuterium ethyls.
In another preference, one or more R 4It is deuterium.
In another preference, one or more R 5It is deuterium.
In another preference, described compound is the preferred compound that is selected from down group:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800031
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1'-two deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800032
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1'-deuterium methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800033
N-(4-chloro-3-(three deuterium methyl) phenyl)-N'-(4-(2-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800034
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(2-deuterium-4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800042
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(2,6-, two deuteriums-4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(three deuterium methyl) phenyl)-N'-(4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-methyl-N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800051
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N, N-two (1', 1', 1'-three deuterium methyl) formamyl)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800052
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(2,6-, two deuteriums-4-(2-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800053
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-deuterium-6-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800054
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1'-two deuterium ethylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800055
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1', 2', 2', 2'-five deuterium ethylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
Figure BDA00003182473800061
Or N-(4-chloro-3-(three deuterium methyl) phenyl)-N'-(4-(2-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea.
In a second aspect of the present invention, a kind of method of pharmaceutical compositions is provided, comprise step: with the compound described in pharmaceutically acceptable carrier and the first aspect present invention, or its crystal formation, pharmacy acceptable salt, hydrate or solvate mix, thereby form pharmaceutical composition.
In a third aspect of the present invention, a kind of pharmaceutical composition is provided, it is characterized in that it contains the compound described in pharmaceutically acceptable carrier and the first aspect present invention, or its crystal formation, pharmacy acceptable salt, hydrate or solvate.
In another preference, described pharmaceutical composition is injection, wafer, tablet, pill, powder or granule.
In another preference, described pharmaceutical composition also contains other medicine, and described other medicine is the medicine of cancer, cardiovascular disorder, inflammation, immunological disease, ephrosis, blood vessel generation (angiogenesis), prostatosis.
More preferably, described medicine comprises (but being not limited to): 5 FU 5 fluorouracil, AV412, Avastin TM(avastin, bevacizumab), bexarotene (bexarotene), Velcade (bortezomib), calcitriol (calcitriol), how card is for Buddhist nun (canertinib), capecitabine (capecitabine), carbon platinum (carboplatin), celecoxib (celecoxib), Cetuximab (cetuximab), CHR-2797, cis-platinum (cisplatin), Dasatinib (dasatinib), digoxin (digoxin), enzastaurin, erlotinib (Erlotinib), etoposide (etoposide), everolimus (everolimus), fulvestrant (fulvestrant), Gefitinib (gefitinib), 2,2-difluoro deoxycytidine (gemcitabine), Sophoricol (genistein), imatinib (imatinib), Rinotecan (irinotecan), lapatinibditosylate (lapatinib), Revlimid (lenalidomide), letrozole (letrozole), folinic acid (leucovorin), horse trastuzumab (matuzumab), oxaliplatin (oxaliplatin), taxol (paclitaxel), handkerchief Buddhist nun monoclonal antibody (panitumumab), the granulocyte colony-stimulating factor of PEGization (pegfilgrastin), the alpha-interferon of PEGization (peglated alfa-interferon), pemetrexed (pemetrexed);
Figure BDA00003182473800071
E, husky platinum (satraplatin), sirolimus (sirolimus), Xarelto (sorafenib), Sutent (sutent, sunitinib), sulindac (sulindac), taxotere (taxotere), Temozolomide (temodar, temozomolomide), Torisel(temsirolimus), TG01, tipifarnib, trastuzumab (trastuzumab), valproic acid (valproic acid), Vinflunine (vinflunine), Volociximab, vorinostat and XL647.
In a fourth aspect of the present invention, the compound described in the first aspect present invention is provided, or the purposes of its crystal formation, pharmacy acceptable salt, hydrate or solvate, they are used to the pharmaceutical composition that preparation suppresses phosphokinase (as the raf kinases).
In another preference, described pharmaceutical composition is used for the treatment of and prevents following disease: (angiogenesis) or prostatosis take place in cancer, cardiovascular disorder, inflammation, immunological disease, ephrosis, blood vessel.
In another preference, described cancer comprises (but being not limited to): non-minicell lung cancer, uterus carcinoma, the rectum cancer, the cancer of the brain, a cancer, neck cancer, bladder cancer, prostate cancer, mammary cancer, solid tumor, kidney, leukemia, liver cancer, cancer of the stomach or carcinoma of the pancreas.
In a fifth aspect of the present invention, a kind of methods for the treatment of is provided, it comprises step: use the compound described in the first aspect present invention for the object of needs treatment, or its crystal formation, pharmacy acceptable salt, hydrate or solvate, or use the pharmaceutical composition described in the third aspect present invention, thereby suppress phosphokinase (as the raf kinases).
Description of drawings
Fig. 1 is serum drug level (ng/ml) graphic representation behind the oral 3mg/kg control compound of the male SD rat CM4306.
Fig. 2 is serum drug level (ng/ml) graphic representation behind the oral 3mg/kg The compounds of this invention of the male SD rat CM4307.
Embodiment
The inventor is through research, be surprised to find that, ω-the diphenyl urea in deuterium of the present invention generation and pharmacy acceptable salt thereof are compared with the compound without deuterium generation, have obviously more excellent pharmacokinetics and/or pharmacodynamics performance, therefore be more suitable for the kinase whose compound as inhibition raf, and then the medicine of more suitable preparation treatment cancer and relative disease.Finished the present invention on this basis.
With deuterium for compound N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 '; 1 '; 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea (Compound C M4307) and not N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-methylamino the formyl radical)-4-pyridyl oxygen) phenyl) urea (Compound C M4306) in deuterium generation be example
Figure BDA00003182473800081
The pharmacokinetics experimental result shows that CM4307 is than the transformation period T of CM4306 1/2Prolong area under curve AUC 0-∞CM4307 is than the remarkable increase of CM4306, and CM4307 reduces than the apparent clearance rate of CM4306.
Definition
As used herein, " halogen " refers to F, Cl, Br and I.More preferably, halogen atom is selected from F, Cl and Br.
As used herein, " alkyl " comprises the alkyl of straight or branched.Preferred alkyl is the C1-C4 alkyl, for example methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl etc.
As used herein, " deuterium generation " refers to that the one or more hydrogen in compound or the group are replaced by deuterium.Deuterium is for being a replacement, two replacements, polysubstituted or full replacement.
In another preference, deuterium is greater than natural deuterium isotopic content (0.015%), more preferably greater than 50% in the deuterium isotopic content of deuterium the position of substitution, more preferably greater than 75%, more preferably greater than 95%, more preferably greater than 97%, more preferably greater than 99%, more preferably greater than 99.5%.
In another preference, formula (I) compound contains 1 D atom at least, more preferably 3 D atoms, more preferably 5 D atoms.
Activeconstituents
As used herein, term " The compounds of this invention " refers to the compound shown in the formula (I).This term also comprises and various crystalline forms, pharmacy acceptable salt, hydrate or the solvate of formula (I) compound.
As used herein, term " pharmacy acceptable salt " refers to the formed salt that is suitable as medicine of The compounds of this invention and acid or alkali.Pharmacy acceptable salt comprises inorganic salt and organic salt.The preferred salt of one class is The compounds of this invention and the sour salt that forms.The acid that is fit to formation salt includes, but are not limited to: mineral acids such as hydrochloric acid, Hydrogen bromide, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, propanedioic acid, succsinic acid, fumaric acid, toxilic acid, lactic acid, oxysuccinic acid, tartrate, citric acid, picric acid, methylsulfonic acid, benzene methanesulfonic acid, organic acids such as Phenylsulfonic acid; And acidic amino acid such as aspartic acid, L-glutamic acid.
The preparation method
More specifically describe the preparation method of formula of the present invention (I) structural compounds below, but these concrete grammars do not constitute any restriction to the present invention.The compounds of this invention can also be chosen various synthetic methods that will describe in this manual or known in the art wantonly and combine and make easily, and such combination can be easy to carry out by those skilled in the art in the invention.
The preparation method of the ω-diphenyl urea in the present invention uses not deuterium generation and the salt of physical compatibility thereof is known.The preparation of the ω-diphenyl urea in corresponding deuterium generation can be raw material for initial compounds with corresponding deuterium, synthesizes with same route.For example, formula of the present invention (I) compound can be by the preparation method described in WO2000/042012 preparation, and difference is to be used for deuterium generation in reaction raw material replaces the non-deuterium raw material in generation.
Usually, in preparation flow, each reaction in inert solvent, is carried out to reflux temperature (as 0 ℃～80 ℃, preferred 0 ℃～50 ℃) in room temperature usually.Reaction times was generally 0.1 hour-60 hours, preferably was 0.5-48 hour.
Be example with Compound C M4307, a kind of particularly preferred preparation flow is as follows:
Figure BDA00003182473800101
In deuterium generation, can introduce for methylamine by deuterium.Deuterium also can be by the following method preparation of known literature method, as the hydrogenation hydrogenation reaction of deuterium for Nitromethane 99Min. for methylamine.
Figure BDA00003182473800102
In the formula, r.t. represents room temperature.
Key intermediate 3 also can be synthetic from deuterated methanol by the following method.
Its concrete synthetic method has detailed explanation in embodiment 1.
Pharmaceutical composition and application process
Because The compounds of this invention has excellent in phosphokinase (Kinase) kinase whose the inhibitions activity of raf for example, so The compounds of this invention and various crystal formation thereof, pharmaceutically acceptable inorganic or organic salt, hydrate or solvate, and to contain The compounds of this invention be that the pharmaceutical composition of main active ingredient can be used for treatment, prevention and alleviates by to phosphokinase (Kinase) the kinase mediated disease of raf for example.According to prior art, The compounds of this invention can be used for treating following disease: cancer, cardiovascular disorder, obesity, diabetes etc.
Pharmaceutical composition of the present invention comprises on The compounds of this invention in the safe and effective weight range or its pharmacology acceptable vehicle or carrier on the acceptable salt and pharmacology.Wherein " safe and effective amount " refers to: the amount of compound is enough to obviously improve the state of an illness, and is unlikely to produce severe side effect.Usually, pharmaceutical composition contains 1-2000mg The compounds of this invention/agent, more preferably, contains 10-200mg The compounds of this invention/agent.Preferably, described " potion " is a capsule or tablet.
" pharmaceutically acceptable carrier " refers to: one or more consistency solids or liquid filler or gelatinous mass, they are suitable for the people uses, and enough purity and enough low toxicity must be arranged." consistency " referred to herein as each component energy and compound of the present invention and blending mutually between them in the composition, and the drug effect of not obvious reduction compound.Pharmaceutically acceptable carrier part example has Mierocrystalline cellulose and derivative (as Xylo-Mucine, ethyl cellulose sodium, cellulose ethanoate etc.) thereof, gelatin, talcum, solid lubricant (as stearic acid, Magnesium Stearate), calcium sulfate, vegetables oil (as soya-bean oil, sesame oil, peanut oil, olive wet goods), polyvalent alcohol (as propylene glycol, glycerine, N.F,USP MANNITOL, sorbyl alcohol etc.), emulsifying agent (as tween
Figure BDA00003182473800111
), wetting agent (as sodium lauryl sulphate), tinting material, seasonings, stablizer, antioxidant, sanitas, apirogen water etc.
The method of application of The compounds of this invention or pharmaceutical composition is not particularly limited, and representational method of application comprises (but being not limited to): in oral, the knurl, rectum, parenteral (intravenously, intramuscular or subcutaneous) and topical.
The solid dosage that is used for oral administration comprises capsule, tablet, pill, powder and granule.In these solid dosages, active compound mixes with at least a conventional inert excipient (or carrier), as Trisodium Citrate or Lin Suanergai, or mixes with following compositions: (a) filler or expanding material, for example, starch, lactose, sucrose, glucose, N.F,USP MANNITOL and silicic acid; (b) tackiness agent, for example, Walocel MT 20.000PV, alginate, gelatin, Polyvinylpyrolidone (PVP), sucrose and gum arabic; (c) wetting Agent for Printing Inks, for example, glycerine; (d) disintegrating agent, for example, agar, calcium carbonate, yam starch or tapioca (flour), alginic acid, some composition silicate and yellow soda ash; (e) retarding solvent, for example paraffin; (f) absorb accelerator, for example, quaternary ammonium compound; (g) wetting agent, for example hexadecanol and glyceryl monostearate; (h) sorbent material, for example, kaolin; (i) lubricant, for example, talcum, calcium stearate, Magnesium Stearate, solid polyethylene glycol, sodium lauryl sulphate, or its mixture.In capsule, tablet and the pill, formulation also can comprise buffer reagent.
Solid dosage such as tablet, sugar-pill, capsule, pill and granule can adopt dressing and the preparation of shell material, as casing and other material well known in the art.They can comprise opacifying agent, and, discharge in the mode that the release of active compound or compound can postpone in this composition certain part in digestive tube.The example of adoptable embedding component is polymeric material and Wax.In case of necessity, active compound also can with above-mentioned vehicle in one or more form microencapsulation form.
The liquid dosage form that is used for oral administration comprises pharmaceutically acceptable emulsion, solution, suspension, syrup or tincture.Except the active ingredient beyond the region of objective existence, liquid dosage form can comprise the conventional inert diluent that adopts in this area, as water or other solvent, solubilizing agent and emulsifying agent, example is known, the mixture of ethanol, Virahol, ethyl-carbonate, ethyl acetate, propylene glycol, 1,3 butylene glycol, dimethyl formamide and oil, particularly Oleum Gossypii semen, peanut oil, maize germ, sweet oil, Viscotrol C and sesame oil or these materials etc.
Except these inert diluents, composition also can comprise auxiliary agent, as wetting agent, emulsifying agent and suspension agent, sweeting agent, the agent of tender flavor and spices.
Except the active ingredient beyond the region of objective existence, suspension can comprise suspension agent, for example, and the mixture of ethoxylation isooctadecane alcohol, polyoxyethylene sorbitol and Isosorbide Dinitrate, Microcrystalline Cellulose, aluminum methylate and agar or these materials etc.
The composition that is used for parenteral injection can comprise physiologically acceptable aseptic moisture or anhydrous solution, dispersion liquid, suspension or emulsion and be used for being dissolved into again aseptic Injectable solution or the sterilized powder of dispersion liquid.Suitable moisture and nonaqueous carrier, thinner, solvent or vehicle comprise water, ethanol, polyvalent alcohol and suitable mixture thereof.
The formulation that is used for the The compounds of this invention of topical comprises ointment, powder, patch, propellant and inhalation.Activeconstituents under aseptic condition with physiologically acceptable carrier and any sanitas, buffer reagent, or the propelling agent that may need in case of necessity is mixed together.
The compounds of this invention can be individually dosed, perhaps with other pharmaceutically acceptable compound Combined Preparation.
When making pharmaceutical composition, it is the Mammals (as the people) that the The compounds of this invention of safe and effective amount is applicable to the needs treatment, the effective dosage of dosage for pharmaceutically thinking when wherein using, for the people of 60kg body weight, day dosage is generally 1～2000mg, preferred 20～500mg.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
Compound of the present invention is compared with the compound that does not carry deuterium well known in the prior art, has series of advantages.Major advantage of the present invention comprises:
(1) The compounds of this invention to phosphokinase (Kinase) for example the raf kinases have excellent inhibition.
(2) by the metabolism in this technology change organism of deuterate, make the metabolism of medicine become difficult, this causes the reduction of first pass effect (First-pass effect).In this case, can change dosage and form prolonged action preparation, the form that it also can prolonged action preparation is improved suitability.
(3) also changed the pharmacokinetics effect by deuterate, because deuterium is completed into another hydrate film for compound, so that distribution in organism obviously is different from the compound in generation of deuterium not.
(4) with the hydrogen atom in the deuterium substitution compound, because its isotopic effect can improve compound drug level in animal body, to improve curative effect of medication.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used for explanation the present invention and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, or the condition of advising according to manufacturer.Unless otherwise indicated, otherwise umber and per-cent are weight part and weight percent.
Embodiment 1:N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea (Compound C M4307)
Synthetic route:
Figure BDA00003182473800131
Flow process 1
1, the preparation of 4-chloropyridine-2-(1'-three deuteriums are for methyl for N-1', 1') methane amide (3)
In the single neck round-bottomed flask of the 250mL that is furnished with exhaust gas processing device, add sulfur oxychloride (60mL), holding temperature is between 40～50 ℃, to wherein dripping dry DMF (2mL) slowly, after dropwising, continue to stir 10 minutes, in 20 minutes to wherein add nicotinic acid (20g in batches, 162.6mmol), the color of solution is lilac by green transition gradually.Temperature is raised to 72 ℃, and stirring and refluxing 16 hours produces a large amount of solid sediments.Cool to room temperature with toluene (100mL) dilution, is concentrated near doing, and then uses dilution with toluene, is concentrated into dried.Filter, use toluene wash, obtain flaxen 3-chloro-pyridine-2-formyl chloride solid.With this solid joining in the tetrahydrofuran (THF) saturated solution of deuterium for methylamine slowly, holding temperature is lower than 5 ℃ under the ice bath, continues to stir 5 hours.Concentrate, add ethyl acetate, separate out white solid, filtering, filtrate is used the saturated common salt water washing, and anhydrous sodium sulfate drying is concentrated into driedly, obtains flaxen 4-chloropyridine-2-(1'-three deuteriums are for methyl for N-1', 1') methane amide (3) (20.68g), yield 73%.
1H?NMR(CDCl 3,300MHz):　　8.37(d,1H),8.13(s,1H),7.96(br,1H),7.37(d,1H).
2, the preparation of 4-(4-ammonia phenoxy group)-2-pyridine-(1'-three deuteriums are for methyl for N-1', 1') methane amide (5)
Add successively in the dry DMF of 100mL drying p-aminophenol (9.54g, 0.087mol), potassium tert.-butoxide (10.3g, 0.092mol), solution becomes Vandyke brown, stirs under the room temperature after 2 hours, to wherein adding 4-chloropyridine-2-(N-1', 1', 1'-three deuteriums are for methyl) and methane amide (3) (13.68g, 0.079mol), Anhydrous potassium carbonate (6.5g, 0.0467mol), continue to stir after reacting liquid temperature is raised to 80 ℃ and spend the night.The TLC detection reaction finishes, and cool to room temperature is poured reaction solution in the mixed solution of ethyl acetate (150mL) and saturated aqueous common salt (150mL), stir layering, leave standstill the back separatory, water layer ethyl acetate extraction (100mL * 3), combining extraction liquid, with saturation water washing (100mL * 3), anhydrous sodium sulfate drying, concentrate, obtain flaxen 4-(4-ammonia phenoxy group)-2-pyridine-(N-1', 1', 1'-three deuteriums are for methyl) methane amide (18.00g), yield 92%.
1H?NMR(CDCl 3,300MHz):8.32(d,1H),7.99(br,1H),7.66(s,1H),6.91～6.85(m,3H),6.69(m,2H),3.70(br,s,2H).
3, the preparation of N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea (CM4307)
In the 120mL methylene dichloride, add 5-amino-2-chloro-trifluoromethylbenzene (15.39g, 78.69mol), N, and N'-carbonyl dimidazoles (CDI) (13.55g, 83.6mmol), after the stirring at room 16 hours, to wherein dripping 4-(4-ammonia phenoxy group)-2-pyridine-(1'-three deuteriums are for methyl for N-1', 1') methane amide (18g slowly, methylene dichloride 73mmol) (180mL) solution continues under the room temperature to stir 18 hours.The TLC detection reaction finishes, and revolves the part methylene chloride solvent to the 100mL, and room temperature is placed a few hours, has a large amount of white solids to separate out, a large amount of washed with dichloromethane of suction filtration, solid.After filtrate concentrating removed partial solvent; separate out the part solid again; merge solid twice; wash again with a large amount of methylene dichloride; obtain N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1' of white powdery; 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) the pure product of urea CM4307 (20.04g), yield 58%.
1H?NMR(CD 3OD,300MHz):8.48(d,1H),8.00(d,1H),7.55(m,5H),7.12(d,1H),7.08(s,2H),ESI-HRMS?m/z:C21H13D3ClF3N4O3,Calcd.467.11,Found490.07(M+Na) +.
The preparation of embodiment 2:4-chloropyridine-2-(1'-three deuteriums are for methyl for N-1', 1') methane amide (3)
Figure BDA00003182473800151
A) with phthalic imidine (14.7g, 0.1mol), deuterated methanol (3.78g, 0.105mol, 1.05equiv), triphenylphosphine (28.8g, 0.11mol, 1.1equiv) be dissolved in the anhydrous tetrahydro furan, drip the tetrahydrofuran solution of DEAD (1.1equiv) under the ice bath, dropwised the back stirring at room one hour.Cross post and purify, after perhaps solvent is spin-dried for, add an amount of DCM in the freezing solid after-filtration of separating out of refrigerator, filtrate is spin-dried for, and the quick post of crossing gets pure product deuterium for methyl phthalimide 14.8g again.Yield 90%.
B) deuterium is for methyl phthalimide (12.5g, 0.077mol) be dissolved in appropriate hydrochloric acid (6N, 50ml), in tube sealing backflow 24-30 hour, after reaction solution is cooled to room temperature, place refrigerator and cooled but to arrive sub-zero zero, the solid that filtration is separated out, with cold deionized water wash, collect filtrate, revolve to steam and dewater and drying obtains deuterium for methylamine hydrochloride.Add anhydrous DCM (100ml) in deuterium for methylamine hydrochloride in, and (0.5equiv), (1.5equiv), the reaction flask sealing places refrigerator reaction one day to yellow soda ash for 12.2g, 0.12mol for 6.52g, 0.038mol to add 4-chlorine apellagrin methyl ester hydrochloride.The TLC detection reaction, the after washing that finishes, drying concentrates, and crosses post and purifies.Get compound 4-chloro pyridine-2-(1'-three deuteriums are for methyl for N-1', 1') methane amide (3), 5.67g, yield 86%.Its constitutional features is consistent with embodiment 1.
The preparation of embodiment 3 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1'-two deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800161
Press the method described in the embodiment 1, difference is: use CD 2HNH 2Replace CD 3NH 2Thereby, make target compound.
The preparation of embodiment 4 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1'-deuterium methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800162
Press the method described in the embodiment 1, difference is: use CDH 2NH 2Replace CD 3NH 2Thereby, make target compound.
The preparation of embodiment 5 compound Ns-(4-chloro-3-(three deuterium methyl) phenyl)-N'-(4-(2-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800163
Press the method described in the embodiment 1, difference is: replace 5-amino-2-chloro-trifluoromethylbenzene, CH with 5-amino-2-chloro-three deuterium methylbenzene 3NH 2Replace CD 3NH 2Thereby, make target compound.
The preparation of embodiment 6 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800171
Press the method described in the embodiment 1, difference is: replace nicotinic acid, CH with 2-deuterium-6-carboxyl pyridine 3NH 2Replace CD 3NH 2Thereby, make target compound.
Embodiment 7 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(2-deuterium-4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
Press the method described in the embodiment 1, difference is: replace nicotinic acid with 2-deuterium-6-carboxyl pyridine, 3-deuterium-4-amino-phenol is replaced p-aminophenol, CH 3NH 2Replace CD 3NH 2Thereby, make target compound.
The preparation of embodiment 8 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(2,6-, two deuteriums-4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800173
Press the method described in the embodiment 1, difference is: replace nicotinic acid with 2-deuterium-6-carboxyl pyridine, 3,5-, two deuteriums-4-amino-phenol is replaced p-aminophenol, CH 3NH 2Replace CD 3NH 2Thereby, make target compound.
The preparation of embodiment 9 compound Ns-(4-chloro-3-(three deuterium methyl) phenyl)-N'-(4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800181
Press the method described in the embodiment 1, difference is: replace nicotinic acid with 2-deuterium-6-carboxyl pyridine, replace 5-amino-2-chloro-trifluoromethylbenzene, CH with 5-amino-2-chloro-three deuterium methylbenzene 3NH 2Replace CD 3NH 2Thereby, make target compound.
The preparation of embodiment 10 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-methyl-N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800182
Press the method described in the embodiment 1, difference is: use CD 3CH 3NH replaces CD 3NH 2Thereby, make target compound.
The preparation of embodiment 11 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N, N-two (1', 1', 1'-three deuterium methyl) formamyl)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800183
Press the method described in the embodiment 1, difference is: use CD 3CD 3NH replaces CD 3NH 2Thereby, make target compound.
The preparation of embodiment 12 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(2,6-, two deuteriums-4-(2-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800191
Press the method described in the embodiment 1, difference is: use CD 2HNH 2Replace CD 3NH 2, 3,5-, two deuteriums-4-amino-phenol is replaced p-aminophenol, thereby makes target compound.
The preparation of embodiment 13 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-deuterium-6-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: replace nicotinic acid with 2-deuterium-6-carboxyl pyridine, thereby make target compound.
The preparation of embodiment 14 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1'-two deuterium ethylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800193
Press the method described in the embodiment 1, difference is: CH 3CD 2NH 2Replace CD 3NH 2Thereby, make target compound.
The preparation of embodiment 15 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1', 1', 2', 2', 2'-five deuterium ethylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: CD 3CD 2NH 2Replace CD 3NH 2Thereby make target compound.
The preparation of embodiment 16 compound Ns-(4-chloro-3-(three deuterium methyl) phenyl)-N'-(4-(2-(N-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Figure BDA00003182473800202
Press the method described in the embodiment 1, difference is: replace 5-amino-2-chloro-trifluoromethylbenzene with 5-amino-2-chloro-three deuterium methylbenzene, thereby make target compound.
Embodiment 17: the pharmacokinetics evaluation in the rat
8 male Sprague-Dawley rats, in age in 7-8 week, the about 210g of body weight is divided into 2 groups, and 4 every group (rat is numbered: control group is 13-16; Experimental group is 9-12); single oral gives 3mg/kg dosage (a) to composition: not N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-methylamino the formyl radical)-4-pyridyl oxygen) phenyl) urea (control compound CM4306) in deuterium generation or (b) N-(4-chloro-3-(trifluoromethyl) the phenyl)-N ' of embodiment 1 preparation-(4-(2-(N-1 '; 1 '; 1 '-three deuterium methylamino formyl radicals)-and 4-pyridyl oxygen) phenyl) urea (The compounds of this invention CM4307), relatively its pharmacokinetic difference.
Rat adopts standard feed to raise, and gives water and zeisin.Stop to give zeisin the evening before that day of experiment, gave zeisin after the administration in 2 hours again.Test beginning fasting in preceding 16 hours.Medicine dissolves with 30%PEG400.Eye socket blood sampling, the time point of blood sampling are after the administration 0.083 hour, 0.25 hour, and 0.5 hour, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours.
Make rat suck of short duration anesthesia behind the ether, eye socket is gathered the 300uL blood sample in test tube.30ul1% heparinate solution is in vitro arranged.Before the use, test tube spends the night in 60 ℃ of oven dry.After a time point blood specimen collection is finished subsequently, put to death behind the rat etherization.
After the blood specimen collection, leniently put upside down test tube at least 5 times immediately, guarantee to be positioned on ice after the mixing fully.Blood sample separates serum centrifugal 5 minutes of 4 ℃ of 5000rpm with red corpuscle.In clean plastic centrifuge tube, show title and the time point of compound with pipettor sucking-off 100uL serum.Serum is carrying out being kept at-80 ℃ before LC-MS analyzes.
Its result is shown in Fig. 1-2.The result shows that CM4307 is than the transformation period T of CM4306 1/2Prolong [being respectively 11.3 ± 2.1 hours and 8.6 ± 1.4 hours] area under curve AUC 0-∞CM4307 is than the remarkable increase of CM4306 [being respectively 11255 ± 2472ngh/mL and 7328 ± 336ngh/mL], and CM4307 reduces [being respectively 275 ± 52mL/h/kg and 410 ± 18.7mL/h/kg] than the apparent clearance rate of CM4306.
Find out that from top result The compounds of this invention has better medicament kinetics in animal body, thereby have better pharmacodynamics and regulation effect.
In addition, by deuterate, the metabolic process of The compounds of this invention in organism changes to some extent.Make the hydroxylation on the phenyl become difficult especially, this causes the reduction of first pass effect (First-pass effect).In this case, can change dosage and form prolonged action preparation, the form that it also can prolonged action preparation is improved suitability.
In addition, also changed the pharmacokinetics effect by deuterate, because deuterium is completed into another hydrate film for compound, so that distribution in organism obviously is different from the compound in generation of deuterium not.
Embodiment 18 pharmaceutical compositions
Compound C M4307 (embodiment 1) 20g
Starch 140g
Microcrystalline Cellulose 60g
According to a conventional method, after above-mentioned substance mixed, the common gelatine capsule of packing into obtained 1000 capsules.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.

Claims (12)

1. the method for preparation formula 3 compounds is characterized in that, described method comprises step:
(a1) with 1,1,1-, three deuteriums for methylamine hydrochloride by following reaction, thereby form formula 3 compounds:
Figure FDA00003182473700011
Perhaps comprise step:
(b2) with formula 2 compounds by following reaction, thereby form formula 3 compounds:
Figure FDA00003182473700012
2. the compound shown in the formula 3,
3. the purposes of formula 3 compounds is characterized in that, as preparing the intermediate of deuterium for compound shown in diphenyl urea or the formula 5:
Figure FDA00003182473700014
4. the compound shown in the formula 5,
Figure FDA00003182473700015
5. the method for preparation formula 5 compounds is characterized in that, comprises step: by following prepared in reaction formula 5 compounds:
Figure FDA00003182473700021
6. the purposes of formula 5 compounds is characterized in that, as the intermediate of preparation deuterium for diphenyl urea.
7. as claim 3 or 6 described purposes, it is characterized in that described deuterium is formula (I) compound for diphenyl urea:
Figure FDA00003182473700022
Wherein:
R 1It is halogen;
R 2Be the C that whole halogens replace 1-C 4Alkyl;
R 3Be hydrogen;
R 4It is hydrogen or halogen;
R 5Be hydrogen;
R 6Be the full deuterium C in generation 1-C 4Alkyl;
R 7Be hydrogen;
Supplementary condition are R 2, R 3, R 4, R 5, R 6Or R 7In at least one be deuterium generation or deuterium;
More preferably, described deuterium for diphenyl urea is: 4-(4-(3-(4-chloro-3-(trifluoromethyl) phenyl] uride)-phenoxy group)-2-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) picolinamide, i.e. CM4307:
8. the preparation method of a 4-(4-(3-(4-chloro-3-(trifluoromethyl) phenyl] uride)-phenoxy group)-2-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) picolinamide CM4307 is characterized in that, may further comprise the steps: by following prepared in reaction:
Figure FDA00003182473700031
9. ω-diphenyl urea compound or its pharmacy acceptable salt in the deuterium generation shown in the formula (I):
Figure FDA00003182473700032
Wherein:
R 1It is halogen;
R 2Be the C that whole halogens replace 1-C 4Alkyl;
R 3Be hydrogen;
R 4It is hydrogen or halogen;
R 5Be hydrogen;
R 6Be the full deuterium C in generation 1-C 4Alkyl;
R 7Be hydrogen;
Supplementary condition are R 2, R 3, R 4, R 5, R 6Or R 7In at least one be deuterium generation or deuterium;
And supplementary condition are that described compound does not comprise N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N 15-1', 1', 1'-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea.
10. ω-diphenyl urea compound or its pharmacy acceptable salt in deuterium generation; it is characterized in that; described compound is N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4-(2-(N-1'; 1'; 1'-three deuterium methylamino formyl radicals)-and 4-pyridyl oxygen) phenyl) urea, and described compound prepares with embodiment 1 described method.
11. a pharmaceutical composition is characterized in that, it contains arbitrary described compound among pharmaceutically acceptable carrier and the claim 9-10, or its pharmacy acceptable salt.
12. arbitrary described compound among the claim 9-10, or the purposes of its pharmacy acceptable salt is characterized in that, for the preparation of the pharmaceutical composition that suppresses phosphokinase (as the raf kinases); More preferably, described pharmaceutical composition is used for the treatment of and prevents following disease: cancer.
CN2013101761325A 2008-09-19 2008-09-19 Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds Pending CN103254126A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2013101761325A CN103254126A (en) 2008-09-19 2008-09-19 Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013101761325A CN103254126A (en) 2008-09-19 2008-09-19 Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2008102001060A Division CN101676266B (en) 2008-09-19 2008-09-19 Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same

Publications (1)

Publication Number Publication Date
CN103254126A true CN103254126A (en) 2013-08-21

Family

ID=48958394

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013101761325A Pending CN103254126A (en) 2008-09-19 2008-09-19 Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds

Country Status (1)

Country Link
CN (1) CN103254126A (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1341098A (en) * 1999-01-13 2002-03-20 拜尔有限公司 W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
CN1856469A (en) * 2003-07-23 2006-11-01 拜尔医药品股份有限公司 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2007059154A2 (en) * 2005-11-14 2007-05-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
WO2007059155A1 (en) * 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
CN101052619A (en) * 2004-09-29 2007-10-10 拜耳医药保健股份公司 Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
CN101676266B (en) * 2008-09-19 2011-10-26 苏州泽璟生物制药有限公司 Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1341098A (en) * 1999-01-13 2002-03-20 拜尔有限公司 W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
CN1856469A (en) * 2003-07-23 2006-11-01 拜尔医药品股份有限公司 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CN101052619A (en) * 2004-09-29 2007-10-10 拜耳医药保健股份公司 Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
WO2007059154A2 (en) * 2005-11-14 2007-05-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
WO2007059155A1 (en) * 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
CN101676266B (en) * 2008-09-19 2011-10-26 苏州泽璟生物制药有限公司 Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D.J.KUSHNER 等: "Pharmacological uses and perspectives of heavy water and deuterated compounds", 《CAN.J.PHYSIOL.PHARMACOL》 *
U.PLEISS，等: "Syntheses of [2H3,15N],[14C]Nexavar™ and its labeled metabolites", 《JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS》 *
赵乘有,等: "对甲苯磺酸索拉非尼的合成", 《中国医药工业杂志》 *

Similar Documents

Publication Publication Date Title
CN101676266B (en) Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same
CN102190616B (en) A kind of deuterated synthesis of ω-diphenyl urea and the Method and process of production
EP4282416A2 (en) Process of manufacture of a compound for inhibiting the activity of shp2
CN104109149A (en) Deuterated diamino pyrimidine compound and pharmaceutical composition containing same
CN103965114B (en) Deuterated phenyl amino pyrimidine compounds and comprise the pharmaceutical composition of this compound
CN103159680A (en) Imidazole diketone compound and application thereof
CN104024262A (en) Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof
CN102311410A (en) Preparation method for cabazitaxel
CN106478605A (en) Pyrimidines, its preparation method and medical usage
WO2011113203A1 (en) Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds
AU2021383928A1 (en) Fgfr inhibitors and methods of making and using the same
CN102675018A (en) Method for preparing deuterated diphenyl urea
WO2010060387A1 (en) The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof
US20150065719A1 (en) Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
CN104817559A (en) Deuterated quinazolone compound and medical compositions containing same
CN105669532B (en) Nimodipine soluble derivative and its preparation method and application
WO2018157411A1 (en) Substituted nitrogen-containing aromatic compound and application thereof
CN102516154B (en) Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same
CN103254126A (en) Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds
CN102225954A (en) Method for purifying platinum
CN102803221B (en) Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising these compounds
CN114163479A (en) Platinum compounds for treating cancer and preparation method thereof
CN105949117B (en) Sorafenib derivative of the similar structures containing chalcone and its preparation method and application
JP2014500333A (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods of preparing and using same
WO2024074080A1 (en) Anti-influenza virus derivative and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130821